Cirrhosis/Liver Failure News

Patients with alcoholic cirrhosis had a significantly higher risk for hip fracture and post-hip fracture mortality compared with the general population, according to recently published data.

Conatus Pharmaceuticals completed enrollment in its ENCORE-PH phase 2 clinical trial for emricasan, an orally-active pan-caspase inhibitor designed to treat nonalcoholic steatohepatitis-related cirrhosis, according to a press release.

Patients with class III obesity have an increased risk for acute-on-chronic liver failure and a higher prevalence of renal failure as a component of ACLF, according to a recently published study.

PARIS — Patients who underwent fecal microbiota transplant for recurrent hepatic encephalopathy had a lower risk for hospitalization and showed improve gut microbiome and brain function, according to this exclusive interview from the International Liver Congress 2018.

PARIS — GR-MD-02, a novel galectin-3 protein, did not improve hepatic venous pressure gradient in patients with nonalcoholic steatohepatitis and cirrhosis; however, the inhibitor did significantly improve hepatocyte ballooning, according to a presentation at the International Liver Congress 2018.

PARIS — Patients who underwent primary prophylaxis treatment for spontaneous bacterial peritonitis had poorer outcomes compared with patients who previously experienced at least one episode and underwent secondary treatment, according to a presentation at the International Liver Congress 2018.

PARIS — In a disease that has no current treatment, a plasma transfer system may offer hope to patients with alcoholic liver disease, according to a poster at the International Liver Congress 2018.

PARIS — Alcohol abstinence did not reduce the risk for hepatocellular carcinoma among patients with Child-Pugh class A or B alcohol-related cirrhosis, according to a presentation at the International Liver Congress 2018.

Adults who drank about 100 g of alcohol per week had the lowest risk for all-cause mortality compared with other amounts, according to an analysis published in The Lancet.

PARIS — All-cause hospitalizations, rate of emergency visits and inpatient costs increased by more than 90% following compensated cirrhosis diagnosis among patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis, according to a presentation at the International Liver Congress 2018.